J. Xiang

发表

Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.

J. D. Elliott, Yonghui Wang, Zhijun Xiang, 2014, ACS medicinal chemistry letters.

Pyridine-derived γ-secretase modulators.

J. D. Elliott, Zehong Wan, Wei Zhao, 2011, Bioorganic & medicinal chemistry letters.

XP13512 [(±)-1-([(α-Isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane Acetic Acid], A Novel Gabapentin Prodrug: I. Design, Synthesis, Enzymatic Conversion to Gabapentin, and Transport by Intestinal Solute Transporters

R. Barrett, M. Gallop, T. Chernov-Rogan, 2004, Journal of Pharmacology and Experimental Therapeutics.

Chapter 20. Pharmacology of Cannabinoid Receptor Agonists and Antagonists

John C. Lee, J. Xiang, 1999 .

Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.

J. D. Elliott, D. Veber, R. Hertzberg, 2004, Journal of medicinal chemistry.

Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists.

Wei Zhang, Xichen Lin, R. Copley, 2018, Journal of medicinal chemistry.

Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.

J. D. Elliott, Wei Zhang, Yan Xu, 2016, ACS medicinal chemistry letters.

Stereochemical control in the ester enolate Claisen rearrangement. 2. Chairlike vs boatlike transition-state selection

P. Wipf, J. Xiang, R. Ireland, 1991 .

Indole-propionic acid derivatives as potent, S1P3-sparing and EAE efficacious sphingosine-1-phosphate 1 (S1P1) receptor agonists.

J. D. Elliott, Wei Zhang, Yan Xu, 2012, Bioorganic & medicinal chemistry letters.

A novel series of ETA selective antagonists

J. D. Elliott, E. Ohlstein, P. Nambi, 2002 .

Pharmacologic characterization of the novel, orally available endothelin-A--selective antagonist SB 247083.

J. D. Elliott, J. Luengo, S. Douglas, 1998, Journal of cardiovascular pharmacology.

Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors.

Zehong Wan, A. Reith, P. Bamborough, 2017, Bioorganic & medicinal chemistry letters.

A catalyst-free N–H insertion/Mannich-type reaction cascade of α-nitrodiazoesters

J. D. Elliott, Xichen Lin, Ting Yang, 2013 .

Development of an enantioselective synthetic route to neocarzinostatin chromophore and its use for multiple radioisotopic incorporation.

S. Schaus, Yusheng Wu, A. Myers, 2002, Journal of the American Chemical Society.

ENANTIOSELECTIVE SYNTHESIS OF NEOCARZINOSTATIN CHROMOPHORE AGLYCON

Yusheng Wu, A. Myers, P. M. Harrington, 1996 .

Synthesis and antiviral activity of various 3'-azido analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1, HTLV-III/LAV).

R. Schinazi, W. Prusoff, C. K. Chu, 1988, Journal of medicinal chemistry.

2-Aminopyrimidin-4(1H)-one as the novel bioisostere of urea: discovery of novel and potent CXCR2 antagonists.

J. D. Elliott, Wei Zhang, Xichen Lin, 2014, Bioorganic & medicinal chemistry letters.

A Catalyst‐Free N—H Insertion/Mannich‐Type Reaction Cascade of α‐Nitrodiazoesters.

J. D. Elliott, Xichen Lin, Ting Yang, 2013 .

Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist.

J. D. Elliott, J. Luengo, D. Brooks, 1998, The Journal of pharmacology and experimental therapeutics.

Novel complex crystal structure of prolyl hydroxylase domain-containing protein 2 (PHD2): 2,8-Diazaspiro[4.5]decan-1-ones as potent, orally bioavailable PHD2 inhibitors.

J. D. Elliott, Wei Zhang, Xichen Lin, 2013, Bioorganic & medicinal chemistry.

Discovery of Biaryl Amides as Potent, Orally Bioavailable, and CNS Penetrant RORγt Inhibitors.

J. D. Elliott, Yonghui Wang, Zhijun Xiang, 2015, ACS medicinal chemistry letters.

Discovery of novel 1,2,4-thiadiazole derivatives as potent, orally active agonists of sphingosine 1-phosphate receptor subtype 1 (S1P(1)).

J. D. Elliott, Wei Zhang, Xichen Lin, 2012, Journal of medicinal chemistry.

In vitro permeability screening for identification of orally bioavailable endothelin receptor antagonists

J. D. Elliott, Hung‐Yuan Cheng, E. Ohlstein, 1997 .

Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.

J. D. Elliott, Wei Zhang, Yonghui Wang, 2014, Bioorganic & medicinal chemistry.

Discovery of N-(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent RORγt inverse agonists.

J. D. Elliott, Wei Zhang, Yonghui Wang, 2015, Bioorganic & medicinal chemistry.

Discovery of thiadiazole amides as potent, S1P₃-sparing agonists of sphingosine-1-phosphate 1 (S1P₁) receptor.

J. D. Elliott, Wei Zhang, Yonghui Wang, 2012, Bioorganic & medicinal chemistry letters.

From RORγt Agonist to Two Types of RORγt Inverse Agonists.

Yonghui Wang, M. Lobera, Zhijun Xiang, 2018, ACS medicinal chemistry letters.

Discovery of thiadiazole amides as potent, S1P₃-sparing agonists of sphingosine-1-phosphate 1 (S1P₁) receptor.

J. D. Elliott, Wei Zhang, Yonghui Wang, 2012, Bioorganic & medicinal chemistry letters.

Plasma- and cerebrospinal fluid-immunoreactive endothelin-1: effects of nonpeptide endothelin receptor antagonists with diverse affinity profiles for endothelin-A and endothelin-B receptors.

J. D. Elliott, J. Luengo, R. Willette, 1998, Journal of cardiovascular pharmacology.